Click on the links or scroll down the page for information about work currently in progress by category. Please note that information summarised on this page is subject to change.
We produce prescribing guidance and other medicines resources to help patients and healthcare professionals in Wales make sure that medicines are used effectively and appropriately. When we produce these resources, we think it's important that people who might be affected by them have a chance to tell us their views.
We ask patients and carers, patient organisations, prescribers and other healthcare professionals to comment on the resources we're developing. We'd like your views on the resources we're currently working on, listed below. You don't need to comment on the whole document; only on parts that seem relevant to you.
|
Title: Understanding unlicensed medicines Status: Consultation open - Closing date: 18 November 2022 Remit: This will provide guidance for prescribers across primary and secondary care settings, including clarification around what the different types of unlicensed medicines are, understanding responsibilities throughout the different stages of the prescribing journey and key steps to be taken when prescribing unlicensed medicines and transferring care of relevant patients. Estimated publication date: December 2022-February 2023 |
Patients, carers and patient organisations - please see our New medicines needing your views page for answers to some questions you might have about making a submission.
Clinical experts - please see our Clinical expert opinion for medicine appraisals page for background information.
We'd like to receive your submission before the stated deadline (so we can prepare the meeting papers). But we'll still try to include any that arrive late.
|
Medicine name: levodopa/carbidopa/entacapone (Lecigon®) Reference number: 4871 Indication: Treatment of advanced Parkinson's disease with severe motor fluctuations and hyperkinesia or dyskinesia when available oral combinations of Parkinson medicinal products have not given satisfactory results Patient and carer submission: Download form or submit online Patient organisation submission: Download form or submit online Clinical experts submission: Download form Submission deadline: TBC |
|
Title: All Wales chronic pain resources Status: Consultation completed Remit: Guidelines and resources developed to provide evidence based, prudently-driven guidance for the pharmacological management of chronic pain in Wales. In addition, quick reference guides, patient information leaflets, audit resources and educational materials will also be developed. Estimated publication date: September-November 2022 |
|
Title: Polypharmacy review – guidance for prescribing (2022 update) Status: Consultation completed Remit: This will update and replace the existing ‘Polypharmacy: Guidance for prescribing’ document. The intention of this revision has been to focus the guidance on the groups of medicines commonly prescribed in the elderly population that may require review. Estimated publication date: December 2022-February 2023 |
|
Title: Understanding unlicensed medicines Status: Consultation open - Closing date: 18 November 2022 Remit: This will provide guidance for prescribers across primary and secondary care settings, including clarification around what the different types of unlicensed medicines are, understanding responsibilities throughout the different stages of the prescribing journey and key steps to be taken when prescribing unlicensed medicines and transferring care of relevant patients. |
|
One Wales Medicine new assessment Medicine name: infliximab Reference number: OW21 Indication: Treatment of patients with Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 31/10/2022 OWMAG date: November 2022 |
|
One Wales Medicine new assessment Medicine name: vedolizumab (Entyvio®) Reference number: OW22 Indication: Treatment of patients with Immune Checkpoint Inhibitor (ICI) induced grade 3-4 colitis, where symptoms have not responded to first line immunosuppression with corticosteroids and/or other immunosuppressant drugs like infliximab. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 31/10/2022 OWMAG date: November 2022 |
|
One Wales Medicine new assessment Medicine name: infliximab Reference number: OW23 Indication: Treatment of pulmonary sarcoidosis refractory to standard treatments and when there are no pharmacological alternatives. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 30/11/2022 OWMAG date: December 2022 |
|
One Wales Medicine new assessment Medicine name: vedolizumab (Entyvio®) Reference number: OW24 Indication: Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children.
Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 30/11/2022 OWMAG date: December 2022 |
|
One Wales Medicine new assessment Medicine name: ustekinumab (Stelara®) Reference number: OW25 Indication: Treatment of inflammatory bowel disease (ulcerative colitis and Crohn's disease) in children.
Patients started on anti-TNF would have been started after oral therapy, for example, 5-ASA or azathioprine and/or be considered with severe disease and started on anti-TNF first line. Patient organisation/patient/carer submission: Submit your response by email to awttc@wales.nhs.uk Clinical experts submission: Submit your response by email to awttc@wales.nhs.uk Submission deadline: 30/11/2022 OWMAG date: December 2022 |
|
Title: AWMSG annual report 2022-2023 Summary: Review of the activities and achievements of the All Wales Medicine Strategy Group (AWMSG) between April 2021 and March 2022. Estimated publication date: September 2023 |
|
Title: IPFR annual report 2021-2022 Summary: Review of Individual Patient Funding Request activity in Wales between April 2021 and March 2022. Estimated publication date: September 2022 |